SMO and neoplasm: Mutations affecting proteins involved in HH signaling, including loss of the negative regulator PTCH1 and the activating point mutation in SMO (W535L for human SMO and W539L for mouse Smo), result in hyperactivation of the HH pathway and can lead to cilia-dependent tumor formation in MB [33].